TG Therapeutics, Inc. (TGTX)

TG Therapeutics' stock price has declined since October 2025 due to competitive pressures and investor concerns. Strong Q4 and full-year 2025 revenue results and bullish 2026 guidance led to a surge in shares, but analyst concerns about slower revenue growth caused declines. JPMorgan Chase lowered its price target for TGTX in early February 2026, while maintaining an "Overweight" rating. Ongoing competitive pressures in the multiple sclerosis treatment landscape have contributed to a negative outlook for the stock, which has been trading near the lower end of its 52-week range.

There is no explicit information indicating significant demand seasonality for TG Therapeutics' products and services. The company has reported consistent quarter-over-quarter growth for BRIUMVI revenue. The biopharmaceutical industry can be influenced by factors such as new drug approvals, clinical trial results, and competitive landscape changes, which may impact demand more significantly than traditional seasonal patterns.

TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for B-cell malignancies and autoimmune diseases. Their major approved product is BRIUMVI (ublituximab-xiiy), an anti-CD20 monoclonal antibody approved for relapsing forms of multiple sclerosis (RMS). The company also has a pipeline of investigational medicines, including Ublituximab, TG-1701, Azer-Cel, and TG-1801.

TG Therapeutics generates most of its revenue from BRIUMVI sales in the United States. BRIUMVI is commercialized across Europe and other parts of the world through partners like Neuraxpharm and is currently available in 16 countries globally.

TG Therapeutics' brand reputation has been bolstered by BRIUMVI's strong commercial performance, leading to a #27 ranking on the Deloitte Technology Fast 500 list. However, concerns about slowing growth of BRIUMVI and increased competition in the multiple sclerosis market have presented challenges. Investor sentiment has been influenced by these competitive dynamics and expectations for growth trajectory, despite strong financial results and bullish guidance.

TG Therapeutics, Inc. has a significant institutional ownership base, with 586 institutional owners and shareholders holding a total of 125,017,452 shares. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., and State Street Corp. Michael Weiss, the Chairman, CEO, and President, is also a significant individual owner.